Alaska Chapter of the American College of Cardiology

Latest in Cardiology from ACC.org

• Eagle’s Eye View: Imaging Identifies HCM Patients at High-Risk of Adverse Outcomes
  In this week’s View, Dr. Eagle reviews evidence supporting the use of cardiac magnetic resonance (CMR) and NT-proBNP in hypertrophic cardiomyopathy (HCM) risk assessment.
• New Studies Add to Evidence Involving Optimal Treatment of Patients Post-Ischemic Stroke
  Treatment of patients following ischemic stroke was the focus of three separate studies published in JAMA, two of which involved use of intravenous tenecteplase and the other involving thrombectomy plus intra-arterial alteplase.
• No Child Left Behind: The Case For Early Lipid Screening
  Atherosclerotic cardiovascular disease (ASCVD) is traditionally recognized as a disease of midadulthood. However, atherogenesis begins in childhood. Subclinical atherosclerosis can be detected as early as 8-10 years of age.
• JACC Spotlight Issue Provides Expert Insight on 2026 Dyslipidemia Guideline
  A special JACC Spotlight Issue supporting the recently published 2026 ACC/AHA Guideline on the Management of Dyslipidemia, offers commentaries that provide a comprehensive overview of the new guideline recommendations and expert insights into understanding the science behind the recommendations...
• FDA Update: Agency Approves Baxdrostat to Treat Adults With HTN
  The U.S. Food and Drug Administration (FDA) has approved baxdrostat, a first-in-class oral aldosterone synthase inhibitor, as an add-on therapy for hypertension in adults whose blood pressure (BP) is not adequately controlled with other antihypertensive medications.